Overview

Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)

Status:
Terminated
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and benefit of Thalidomide with primary sclerosing cholangitis (PSC). This is a six month study.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Celgene Corporation
Treatments:
Thalidomide